| Study Title | Start Date | End Date | Description |
|---|---|---|---|
| VX20-121-104 | 2023 | starting soon | A Phase 111, Open-label Study Evaluating the Longterm Safety and Efficacy of VX20-121 Combination Therapy in Subject With Cystic Fibrosis |
| VX20-121-103 | 2022 | ongoing | A Phase 111, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or have at Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation |
| VX20-121-102 | 2022 | ongoing | A Phase 111, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF) |
| VX18-445-113 | 2020 | 2022 | A Phase 111, Open Label Study Evaluating the Long-Term Safety of VX-445 Combination Therapy in Subjects with Cystic Fibrosis |
| VX18-561-101 | 2019 | 2020 | A Phase 11, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis |
| VX18-445-104 | 2019 | 2020 | A Phase 111, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) |
| CFMATTERS FRAMEWORK 7 | 2014 | 2018 | Cystic Fibrosis Microbiome-determined antibiotic trial in exacerbations: results stratified |
| NOVARTIS -CQBW251X2101 | 2016 | 2017 | A randomised double-blind placebo-controlled study to assess the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of single and multiple ascending doses of QBW251 in healthy subjects and multiple doses in cystic fibrosis patients. |
| VERTEX VX14-661-106 | 2016 | 2017 | A phase 111, Randomised, Double-Blind placebo-Controlled, parallel-group study to evaluate the efficacy and safety of VX-661 in Combination with Ivacaftor in subjects aged 12 years and older with Cystic Fibrosis, homozygous for the F508del-CFTRMutation. |
| VERTEX VX14-661-109 | 2016 | 2017 | A phase 111, Randomised, Double-Blind Ivacaftor-Controlled, parallel-group study to evaluate the efficacy and safety of VX-661 in Combination with Ivacaftor in subjects aged 12 years and older with Cystic Fibrosis, heterzygous for the F508del-CFTRMutation and a second CFTR Allele with a gating defect that is clinically demonstrated to be Ivacaftor responsive. |
| VERTEX VX14-661-110 | 2017 | 2019 | A phase 111 open label, rollover study to evaluate the safety and efficacy of long term treatment with VX-661 in Combination with Ivacaftor in subjects aged 12 years and older with Cystic Fibrosis, homozygous or heterzygous for the F508del-CFTRMutation. |
| GALAPAGOD GLPG2222-CL-201 (ALBATROSS STUDY) | 2017 | 2017 | A phase 11a, randomised double blind placebo controlled study to evaluate GLPG2222 in Ivacaftor treated subjects with cystic fibrosis harbouring one F508 del CFTR mutation and a second gating (Class111 mutation) (our centre highest recruiters globally). |
| VERTEX VX16-659-101 | 2017 | 2018 | A phase 11, randomised double blind controlled study to evaluate the safety and efficacy of VX-659 combination therapy in subjects aged 18 years and older with cystic fibrosis. |
| NOVARTIS: CTBM100G2202 | Not yet Commenced | A randomised blinded parallel group multicentre dose finding study, to assess the efficacy, safety and tolerability of different doses of Tobramycin inhalation powder in patients with Non-Cystic Fibrosis Bronchiectasis and pulmonary P.Aeruginosa infection. | |
| VERTEX VX17-659-102 | 2018 | 2019 | A phase 111, randomised, double-blind. Controlled study to evaluate the efficacy and safety of VX-659 combination therapy in subjects with cystic fibrosis who are heterozygous for the F508 del-CFTR Mutation and a minimal function mutation (F/MF). |
| VERTEX VX17-659-103 | 2018 | 2019 | A phase 111, randomised, double-blind, controlled study evaluating the efficacy and safety of VX-659 combination therapy in subjects with cystic fibrosis who are homozygous for the F508del mutation. |
| VERTEX VX17-659-105 | 2018 | 2020 | A phase 111, open label study evaluating the long term safety and efficacy of VX-659 combination therapy in subjects with cystic fibrosis who are homozygous or heterozygous for the F508del mutation. |
| GALAPAGOS GLPG3067-CL-202 | cancelled in 2018 | A phase 11, randomised, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered combination of GLPG3067, GLPG2222 and GLPG2737, in adult subjects with cystic fibrosis homozygous. |